• Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?

  • Jul 5 2022
  • Length: 22 mins
  • Podcast

Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges? cover art

Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?

Listen for free

View show details

  • Summary

  • Joseph Mikhael, MD, and Saad Usmani, MD, discuss options in managing triple-class refractory multiple myeloma including selinexor, belantamab mafodotin, and CAR T-cell therapy.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/964339). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Multiple Myeloma https://emedicine.medscape.com/article/204369-overview

    Selinexor Prescribing Information https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf

    Belantamab Mafodotin Prescribing Information https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Blenrep/pdf/BLENREP-PI-MG.PDF

    Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview

    Trending Clinical Topic: CAR T-cell Therapy https://reference.medscape.com/viewarticle/965011

    Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor https://www.karyopharm.com/wp-content/uploads/2020/06/Consensus-Recommendations_June2020.pdf

    Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932935/

    Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Carfilzomib Nonrefractory Multiple Myeloma (MM) Patients. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8038

    Ide-cel Prescribing Information https://packageinserts.bms.com/pi/pi_abecma.pdf

    Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-label, Phase 2 Study https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(19)30788-0

    DREAMM Trials https://dreammtrials.com/

    Blenrep (Belantamab Mafodotin) REMS https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=403

    Band Keratopathy https://emedicine.medscape.com/article/1194813-overview

    Cilta-cel Prescribing Information https://www.fda.gov/media/156560/download

    BCMA-Directed CAR T-cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT04318327
    Show More Show Less
Show More Show Less

What listeners say about Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.